TIGM inks deal for mice 04 April 2007
The Texas Institute for Genomic Medicine (TIGM) has entered into an agreement with the Myelin Repair Foundation to supply genetically altered mice that United States and Canadian researchers will use to search for the causes of and possible treatments for multiple sclerosis.
TIGM is a Houston-based nonprofit biotech entity founded in 2005.
The Myelin Repair Foundation, headquartered in Saratoga, Calif., is a nonprofit organisation focused exclusively on studying myelin, the protective insulation surrounding nerve fibres of the central nervous system.
Under the terms of the agreement, TIGM will create up to 15 pairs of custom-designed "knockout mice" -- mice that have specific genes altered for myelin research that scientists are conducting at five different locations over the next year.
The MRF has established an accelerated research collaboration process to bring together leading neuroscientists from universities throughout North America to figure out how myelin is created and damaged and how it can be repaired.
Through this non-traditional collaborative process the MRF hopes to bring treatments for multiple sclerosis and other neurological diseases to the public more quickly.
"By getting knockout mice into the hands of MRF researchers at an accelerated pace, TIGM can support MRF in their race to find breakthrough cures for MS," said Dr. Richard Finnell, TIGM executive director.
"TIGM has unique technology to produce the knockout mice we need far more efficiently than we could do it in our own labs," said Rusty Bromley, MRF's chief operating officer.
Source: Houston Business Journal © 2007 American City Business Journals, Inc